PortalPublikationenTime to revise the Dermatology Life Quality Index scoring in...

Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines

Standard

Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. / Rencz, F; Brodszky, V; Gulácsi, L; Péntek, M; Poór, A K; Holló, P; Szegedi, A; Remenyik, É; Sárdy, M; Langenbruch, A; Radtke, M A; Gutknecht, M; Augustin, M.

in: J EUR ACAD DERMATOL, Jahrgang 33, Nr. 7, 33, 07.2019, S. e267-e269.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Rencz, F, Brodszky, V, Gulácsi, L, Péntek, M, Poór, AK, Holló, P, Szegedi, A, Remenyik, É, Sárdy, M, Langenbruch, A, Radtke, MA, Gutknecht, M & Augustin, M 2019, 'Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines', J EUR ACAD DERMATOL, Jg. 33, Nr. 7, 33, S. e267-e269. https://doi.org/10.1111/jdv.15537

APA

Rencz, F., Brodszky, V., Gulácsi, L., Péntek, M., Poór, A. K., Holló, P., Szegedi, A., Remenyik, É., Sárdy, M., Langenbruch, A., Radtke, M. A., Gutknecht, M., & Augustin, M. (2019). Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. J EUR ACAD DERMATOL, 33(7), e267-e269. [33]. https://doi.org/10.1111/jdv.15537

Vancouver

Rencz F, Brodszky V, Gulácsi L, Péntek M, Poór AK, Holló P et al. Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. J EUR ACAD DERMATOL. 2019 Jul;33(7):e267-e269. 33. https://doi.org/10.1111/jdv.15537

Bibtex

@article{d33396c05eef43cbbd32c6cff2594278,
title = "Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines",
abstract = "The treatment of psoriasis has evolved greatly in the past two decades; nevertheless, treatment guidelines across the world have not been updated so often. Currently, most guidelines for psoriasis including those by the European consensus, the European Dermatology Forum, the British Association of Dermatologist and the Medicare Merit-based Incentive Payment System, require the evaluation of health-related quality-of life (HRQoL) in relation to classification of disease severity and/or evaluation of response to treatment.1 In all of these guidelines, HRQoL is advocated to be assessed by the Dermatology Life Quality Index (DLQI) that has been developed in the early 1990s. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "F Rencz and V Brodszky and L Gul{\'a}csi and M P{\'e}ntek and Po{\'o}r, {A K} and P Holl{\'o} and A Szegedi and {\'E} Remenyik and M S{\'a}rdy and A Langenbruch and Radtke, {M A} and M Gutknecht and M Augustin",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = jul,
doi = "10.1111/jdv.15537",
language = "English",
volume = "33",
pages = "e267--e269",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines

AU - Rencz, F

AU - Brodszky, V

AU - Gulácsi, L

AU - Péntek, M

AU - Poór, A K

AU - Holló, P

AU - Szegedi, A

AU - Remenyik, É

AU - Sárdy, M

AU - Langenbruch, A

AU - Radtke, M A

AU - Gutknecht, M

AU - Augustin, M

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/7

Y1 - 2019/7

N2 - The treatment of psoriasis has evolved greatly in the past two decades; nevertheless, treatment guidelines across the world have not been updated so often. Currently, most guidelines for psoriasis including those by the European consensus, the European Dermatology Forum, the British Association of Dermatologist and the Medicare Merit-based Incentive Payment System, require the evaluation of health-related quality-of life (HRQoL) in relation to classification of disease severity and/or evaluation of response to treatment.1 In all of these guidelines, HRQoL is advocated to be assessed by the Dermatology Life Quality Index (DLQI) that has been developed in the early 1990s. This article is protected by copyright. All rights reserved.

AB - The treatment of psoriasis has evolved greatly in the past two decades; nevertheless, treatment guidelines across the world have not been updated so often. Currently, most guidelines for psoriasis including those by the European consensus, the European Dermatology Forum, the British Association of Dermatologist and the Medicare Merit-based Incentive Payment System, require the evaluation of health-related quality-of life (HRQoL) in relation to classification of disease severity and/or evaluation of response to treatment.1 In all of these guidelines, HRQoL is advocated to be assessed by the Dermatology Life Quality Index (DLQI) that has been developed in the early 1990s. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1111/jdv.15537

DO - 10.1111/jdv.15537

M3 - Other (editorial matter etc.)

C2 - 30821001

VL - 33

SP - e267-e269

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 7

M1 - 33

ER -